ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Catabasis, Duchenne UK announce partnership to evaluate edasalonexent in phase 2 non-ambulatory DMD trial
January 13, 2020Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for ... -
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent
September 27, 2018Catabasis announced the initiation of PolarisDMD, the company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy (DMD). Edasalonexent inhibits NF-kB, which is the key link between loss of dystrophin and disease pathology and plays a fundamen
Pharma Sources Insight January 2025
